Compare Carlyle Group Inc (CG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Novo Nordisk A/S — how do they compare? Carlyle Group Inc trades at $47.62 (market cap $17.23B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 12.1× Carlyle Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CG | NVO | |
|---|---|---|
Market Cap | $17.23B | $207.85B |
Sector | Financials | Health |
52-Week High | $69.35 | $63.98 |
52-Week Low | $40.52 | $35.29 |
Dividend Yield | 2.9% | 3.81% |
Enterprise Value | — | $222.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $47.80, up 0.02% daily, with a bullish technical signal from moving averages and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat expectations, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility, declining to $2.8B in 2026 from $3.2B in 2025. The company maintains a dividend of $0.35 per share and has strong institutional interest, with 53.84% of analysts rating it a Buy.
The outlook for CG is positive due to earnings beats and analyst optimism, but risks include inconsistent cash flow from operations and declining revenue. Investment opportunity lies in potential upside to the price target, supported by fundraising strength and strategic partnerships, though investors should monitor execution risks and macroeconomic pressures.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
